BioSpace News Archive

BioCapital

BioPharmX Cancels Presentation at Oppenheimer’s 28th Annual Healthcare Conference Due to Severe Weather

BioPharmX Corporation announces that it has cancelled its presentation at Oppenheimer’s 28th Annual Healthcare Conference in New York tomorrow, due to the winter storm warnings forecasted for the region.

March 20, 2018
·
1 min read
Biotech Beach

AmpliPhi Biosciences Announces Registered Direct Offering of Common Stock

The offering is expected to close on or about March 22, 2018, subject to customary closing conditions.

March 20, 2018
·
4 min read
Business

Biotechnology Company EpiGentek Backs New Epigenetics Skincare Startup EpigenCare

EpiGentek will work in collaboration with EpigenCare to bring to the consumer market a personalized skincare test based on epigenetic markers.

March 20, 2018
·
3 min read
Policy

BIO Statement of Support for the STRONGER Patents Act

BIO supports balanced reforms to reduce abusive patent practices – both by patent owners and against patent owners.

March 20, 2018
·
2 min read
Pharm Country

OncLive® to Host Webinar on Emerging Strategies for Treatment of BRCA-Mutated Breast Cancer

Featured faculty will deliver latest updates in the management of breast cancer

March 20, 2018
·
2 min read
Deals

Notification That All Shares of Hakushindo Pharmaceutical Have Been Acquired by Shinkowa Pharmaceutical Co., Ltd., the First Company in the World to Sell NMN Compound Supplements

Toward the Realization of Academic-industry Integration For True Anti-aging Medicine (Rejuvenation Research)!

March 20, 2018
·
4 min read
Biotech Beach

Advanced Bifurcation Systems Announces Plans for Asian Expansion

Advanced Bifurcation Systems (ABS), a medical stenting technology company, today announced plans to increase their footprint in Asian markets through partnerships in the region.

March 20, 2018
·
2 min read
FDA

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma

Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) in combination with chemotherapy in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.

March 20, 2018
·
8 min read
Business

Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson

Johnson & Johnson announced that Dominic J. Caruso, Executive Vice President, Chief Financial Officer, has elected to retire in September 2018 after a distinguished 19-year career with the Company.

March 20, 2018
·
2 min read
Business

Biotech Big Bangs Its Way Into New York City Via Beacon Capital’s Incubator

Beacon Capital released the introduction of a unique NYC incubator initiative “Beacon Pharma.

March 20, 2018
·
1 min read